Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study.
De Clercq J, De Scheerder MA, Vanherrewege S, Caluwé E, Moreels N, Delooze D, Dhondt A, Coppens M, Vandecasteele SJ, Allard SD, Necsoi C, De Wit S, Gerlo S, Vandekerckhove L. De Clercq J, et al. Among authors: de scheerder ma. J Virus Erad. 2024 Sep 25;10(3):100392. doi: 10.1016/j.jve.2024.100392. eCollection 2024 Sep. J Virus Erad. 2024. PMID: 39403428 Free PMC article.
In depth analysis of the HIV reservoir confirms effectiveness and safety of DTG/3TC in a phase 4 randomized controlled switch trial (RUMBA).
De Scheerder MA, Degroote S, Delporte M, Kiselinova M, Trypsteen W, Vincke L, De Smet E, Van Den Eeckhout B, Schrooyen L, Verschoore M, Muccini C, Vanherrewege S, Caluwe E, De Buyser S, Gerlo S, Blomme E, Vandekerckhove L. De Scheerder MA, et al. J Infect Dis. 2024 Sep 3:jiae405. doi: 10.1093/infdis/jiae405. Online ahead of print. J Infect Dis. 2024. PMID: 39226296
The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis.
Lee MJ, Eason M, Castagna A, Laura G, De Scheerder MA, Riley J, Tebas P, Gunst J, Søgaard O, Florence E, Kroon E, De Souza M, Mothe B, Caskey M, Fidler S. Lee MJ, et al. Among authors: de scheerder ma. J Int AIDS Soc. 2024 Aug;27(8):e26349. doi: 10.1002/jia2.26349. J Int AIDS Soc. 2024. PMID: 39155436 Free PMC article.
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study.
Salgado M, Gálvez C, Nijhuis M, Kwon M, Cardozo-Ojeda EF, Badiola J, Gorman MJ, Huyveneers LEP, Urrea V, Bandera A, Jensen BO, Vandekerckhove L, Jurado M, Raj K, Schulze Zur Wiesch J, Bailén R, Eberhard JM, Nabergoj M, Hütter G, Saldaña-Moreno R, Oldford S, Barrett L, Ramirez MLM, Garba S, Gupta RK, Revollo B, Ferra-Coll C, Kuball J, Alter G, Sáez-Cirión A, Diez-Martin JL, Duke ER, Schiffer JT, Wensing A, Martinez-Picado J; IciStem Consortium. Salgado M, et al. Lancet HIV. 2024 Jun;11(6):e389-e405. doi: 10.1016/S2352-3018(24)00090-0. Lancet HIV. 2024. PMID: 38816141
Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients.
Oyaert M, De Scheerder MA, Van Herrewege S, Laureys G, Van Assche S, Cambron M, Naesens L, Hoste L, Claes K, Haerynck F, Kerre T, Van Laecke S, Jacques P, Padalko E. Oyaert M, et al. Among authors: de scheerder ma. Eur J Clin Microbiol Infect Dis. 2024 Jan;43(1):177-185. doi: 10.1007/s10096-023-04701-x. Epub 2023 Nov 13. Eur J Clin Microbiol Infect Dis. 2024. PMID: 37953413
Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.
Van Praet JT, Serrien B, Ausselet N, Darcis G, Demeester R, De Munter P, De Scheerder MA, Goffard JC, Libois A, Messiaen P, Yombi JC, Van Beckhoven D; Belgian HIV Cohort Study Group. Van Praet JT, et al. Among authors: de scheerder ma. J Acquir Immune Defic Syndr. 2023 Jun 1;93(2):e4-e5. doi: 10.1097/QAI.0000000000003175. J Acquir Immune Defic Syndr. 2023. PMID: 36787727 No abstract available.
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R, Yombi JC, Darcis G, Florence E, Allard SD, De Scheerder MA, Henrard S, Demeester R, Messiaen P, Ausselet N, Loeckx M, Delforge M, De Wit S; Belgian Research on AIDS and HIV Consortium (BREACH). Nasreddine R, et al. Among authors: de scheerder ma. HIV Med. 2023 Mar;24(3):267-278. doi: 10.1111/hiv.13373. Epub 2022 Aug 8. HIV Med. 2023. PMID: 35938381
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022.
Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I, Habibi MS, Apea V, Boesecke C, Vandekerckhove L, Yakubovsky M, Sendagorta E, Blanco JL, Florence E, Moschese D, Maltez FM, Goorhuis A, Pourcher V, Migaud P, Noe S, Pintado C, Maggi F, Hansen AE, Hoffmann C, Lezama JI, Mussini C, Cattelan A, Makofane K, Tan D, Nozza S, Nemeth J, Klein MB, Orkin CM; SHARE-net Clinical Group. Thornhill JP, et al. N Engl J Med. 2022 Aug 25;387(8):679-691. doi: 10.1056/NEJMoa2207323. Epub 2022 Jul 21. N Engl J Med. 2022. PMID: 35866746 Free article.
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial.
Tobback E, Degroote S, Buysse S, Delesie L, Van Dooren L, Vanherrewege S, Barbezange C, Hutse V, Romano M, Thomas I, Padalko E, Callens S, De Scheerder MA. Tobback E, et al. Among authors: de scheerder ma. Int J Infect Dis. 2022 Sep;122:628-635. doi: 10.1016/j.ijid.2022.06.054. Epub 2022 Jul 5. Int J Infect Dis. 2022. PMID: 35803469 Free PMC article. Clinical Trial.
29 results